10 January 2025
Physiomics plc
("Physiomics" or the "Company")
Publication of Peer Reviewed
Article
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce the joint online
publication with Astellas Pharma Inc. ("Astellas") of an original
peer reviewed article "A
Multiple-Model-Informed Drug-Development Approach for Optimal
Regimen Selection of an Oncolytic Virus in Combination with
Pembrolizumab" in the journal "CPT: Pharmacometrics & Systems
Pharmacology". The full article can be accessed via the
following link:
https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/psp4.13297
With cancer being one of the leading causes of
death worldwide, the development of new therapies is critical. One
of the most promising class of oncology therapy is immunotherapy,
an approach that can turn the power of the immune system against
cancer cells. These drugs are either used on their own, or in
combination with other therapies, in order to maximise patient
outcomes.
When developing these types of therapies, one of
the major challenges is around optimising dose and timing (i.e.
treatment scheduling) of the treatment so to balance out any toxic
effect the drug has against the drug's efficacy; its ability to
reduce or eliminate the cancer. This balance becomes even more
complicated when multiple drugs are being used in
combination.
Physiomics adds value to these these processes
by offering drug development companies prediction and optimisation
services through its modelling and simulation capabilities, helping
to predict what treatment dose schedule to explore when progressing
from preclinical research and into the clinical for the first time;
balancing out toxicity with efficacy. These predictions help our
clients focus on the most effective experimental permutations to
explore, thus accelerating and derisking the drug development
process.
Dr Peter
Sargent, CEO, commented: "We are delighted to be able to announce this
peer-reviewed publication. Not only does this paper reflect the
high-quality consultancy services we provided Astellas and the good
relationship we built with them, but it also evidences the power
and utility of our Virtual Tumour Platform in helping to develop
these novel therapies".
In this publication, Physiomics' proprietary
'Virtual Tumour' platform was deployed using a multiple
model-informed drug-development ("MIDD") approach framework to
explore different dose and scheduling strategies. The output of
these models helped describe the expected synergy of a
immunotherapy combination for the purpose of Phase-1 clinical study
design.
This joint publication between Physiomics and
Astellas demonstrates the impact of using modelling and simulation
approaches to accelerate the development of innovative therapies
across a range of therapeutic areas and throughout the entire drug
development pathway, including early discovery and clinical
development. The peer-reviewed article also demonstrates the power
of Physiomics' Virtual Tumour platform in supporting world-leading
pharmaceutical companies develop these important new
therapies.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
